Yuhan Corporation & Samsung Bioepis sign exclusive biosimilar sales agreement

Published: 2017-10-13 16:29:00
Updated: 2017-10-13 15:36:46

Yuhan Corporation(CEO Jung-Hee Lee) signed an exclusive sales agreement of the Remicade(generic name: infliximab) biosimilar(SB2) and the Enbrel(generic name: etanercept) biosimilar(SB4) in Korea with Samsung Bioepis(CEO Han-Seung Ko).

The Remicade biosimilar(SB2) and the Enbrel biosimilar(SB4) ...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.